OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Eskander on Need for Biomarkers in Ovarian Cancer

February 21st 2019

Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses the need for more effective biomarkers in the treatment of patients with ovarian cancer.

Dr. Subudhi Discusses Rationale for CheckMate-650 Study in Prostate Cancer

February 21st 2019

Sumit K. Subudhi, MD, PhD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rationale for the CheckMate-650 study in the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Maziarz on Sustained Responses With Tisagenlecleucel in DLBCL

February 20th 2019

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses sustained responses with tisagenlecleucel in the treatment of patients with diffuse large B-cell lymphoma.

Dr. Holstein Discusses Role of Melflufen in Myeloma

February 20th 2019

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the role of melflufen in the treatment of patients with myeloma.

Dr. Grivas on Unmet Needs in Advanced Urothelial Cancer

February 20th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses unmet needs in the treatment of patients with advanced urothelial cancer.

Dr. Nelson on Novel Combination Therapies in Colorectal Cancer

February 19th 2019

Douglas A. Nelson, MD, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel combination therapies in colorectal cancer (CRC).

Dr. Patel on Induction in Patients With Mantle Cell Lymphoma

February 19th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses induction therapy in patients with mantle cell lymphoma (MCL).

Dr. Shum on Mechanisms of Resistance in Oncogene-Driven NSCLC

February 19th 2019

Elaine Shum, MD, medical oncologist, NYU Langone’s Perlmutter Cancer Center, discusses mechanisms of resistance in patients with oncogene-driven non–small cell lung cancer (NSCLC).

Dr. Weber on FDA Approval of Pembrolizumab for Stage III Melanoma

February 19th 2019

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone's Perlmutter Cancer Center, a 2016 Giant of Cancer Care in Melanoma, discusses the FDA approval of pembrolizumab for stage III melanoma.

Dr. Rayford on the Racial Genomics of Prostate Cancer

February 19th 2019

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses the racial genomics of prostate cancer.

Dr. Davis on Comparisons Between Robotic Surgery and Open Surgery in Lung Cancer

February 19th 2019

J. Russell Davis, MD, clinical professor, University of Missouri–Kansas City School of Medicine, thoracic surgeon, Saint Luke's Hospital, compares the use of robotic surgery with open surgery in patients with lung cancer.

Dr. Ranganath on Treatment Considerations in Nonmetastatic Prostate Cancer

February 19th 2019

Harsha Ranganath, MD, a fellow in the Division of Hematology & Oncology at the University of Tennessee West Cancer Center, discusses treatment considerations in nonmetastatic prostate cancer.

Dr. Goy on Promising Data With Acalabrutinib in MCL

February 19th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses promising data with acalabrutinib in the treatment of patients with mantle cell lymphoma.

Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC

February 19th 2019

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent pembrolizumab in the treatment of patients with advanced renal cell carcinoma.

Dr. George on Sequential Therapy in Metastatic Prostate Cancer

February 15th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequential therapy in metastatic prostate cancer.

Dr. Drilon on Rare Drivers in NSCLC

February 15th 2019

Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering (MSK) Cancer Center, discusses rare drivers in non–small cell lung cancer (NSCLC).

Dr. Mizrahi on Bevacizumab as a Chemoprotectant in CRC

February 15th 2019

Jonathan Mizrahi, MD, hematology/oncology fellow, The University of Texas MD Anderson Cancer Center, discusses bevacizumab (Avastin) as a chemoprotectant in colorectal cancer (CRC).

Dr. Wang on Updated Data With Single-Agent Acalabrutinib in MCL

February 14th 2019

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses updated data with single-agent acalabrutinib in mantle cell lymphoma.

Dr. Kasi on Role of Immunotherapy in mCRC

February 14th 2019

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with metastatic colorectal cancer.

Dr. Decker Discusses AEs Associated With Radiation in Lung Cancer

February 14th 2019

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses common adverse events associated with radiation therapy in the treatment of patients with lung cancer.